Article

ThromboGenics expects microplasmin trial results this year

ThromboGenics NV expects to present the results of two phase III trials evaluating microplasmin for the non-surgical treatment of eye disease later this year.

Leuven, Belgium

-ThromboGenics NV expects to present the results of two phase III trials evaluating microplasmin for the non-surgical treatment of eye disease later this year.

Collectively, the trials are referred to as the MIVI-TRUST (Microplasmin for IntraVitreous Injection-Traction Release without Surgical Treatment) program. One trial (TG-MV-006) is taking place in the United States and the other (TG-MV-007) is taking place in Europe and the United States. Both of the MIVI-TRUST trials are multicenter, randomized, placebo-controlled, double-masked trials evaluating 125 µg of microplasmin versus placebo in the intravitreal treatment of patients with focal vitreomacular adhesion. The endpoint will be measured using optical coherence tomography.

The company expects to present results from the TG-MV-006 study in the second quarter of this year and results from the TG-MV-007 in the third quarter.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
© 2025 MJH Life Sciences

All rights reserved.